

Antipsychotics
Phone: 215-991-4300
Fax back to: 866-240-3712

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

Member Name:	Prescriber Name:	
HPP Member Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Member Primary Phone:	NPI:	PA PROMISE ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Line of Business: <input type="checkbox"/> Medicaid <input type="checkbox"/> CHIP	Specialty Pharmacy (if applicable):	
Drug Name:	Strength:	
Quantity:	Refills:	
Directions:		
Diagnosis Code:	Diagnosis:	
<i>HPP's maximum approval time is 12 months but may be less depending on the drug.</i>		

Please attach any pertinent medical history including labs and information for this member that may support approval.

Please answer the following questions and sign.

Q1. The request is for renewal of the Antipsychotic for a child under 18 years of age that was previously approved. If YES, go to 13. If NO, go to 2.

 Yes

 No

Q2. The request is for a non-preferred Antipsychotic, and the member has a history of therapeutic failure of or a contraindication or an intolerance (such as, but not limited to, diabetes, obesity, etc.) to the preferred Antipsychotics approved or medically accepted for the beneficiary's diagnosis or indication. If YES, go to 4. If NO or Not Applicable, go to 3.

 Yes

 No

 NA

Q3. The member has a current history (within the past 90 days) of being prescribed the same non-preferred Antipsychotic (does not apply to non-preferred brands when the therapeutically equivalent generic is preferred or to non-preferred generics when the therapeutically equivalent brand is preferred).

 Yes

 No

Q4. The request is for Oripiprazole (ariPIPRAZOLE) film, and the member has a contraindication or an intolerance to aripiprazole ODT that would not be expected to occur with Oripiprazole (ariPIPRAZOLE) film.

Antipsychotics
Phone: 215-991-4300
Fax back to: 866-240-3712

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

Member Name:	Prescriber Name:
<input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> NA	
Q5. The request is for an Antipsychotic for a child under the age of 18 years.	
<input type="checkbox"/> Yes <input type="checkbox"/> No	
Q6. The member is age-appropriate according to U.S. Food and Drug Administration (FDA)-approved package labeling, nationally recognized compendia, or peer-reviewed medical literature.	
<input type="checkbox"/> Yes <input type="checkbox"/> No	
Q7. The member has severe symptoms related to psychotic or neuro-developmental disorders such as seen in, but not limited to, the following diagnoses:	
a. Autism spectrum disorder, b. Intellectual disability, c. Conduct disorder, d. Bipolar disorder, e. Mood disorders with psychotic features, f. Tic disorder, including Tourette's syndrome, g. Transient encephalopathy, h. Schizophrenia and schizophrenia-related disorders,	
<input type="checkbox"/> Yes <input type="checkbox"/> No	
Q8. The member has chart documented evidence of a comprehensive evaluation.	
<input type="checkbox"/> Yes <input type="checkbox"/> No	
Q9. The member has a documented plan of care that includes non-pharmacologic therapies (e.g., evidence-based behavioral, cognitive, and family based therapies) when indicated according to national treatment guidelines.	
<input type="checkbox"/> Yes <input type="checkbox"/> No	
Q10. For an Antipsychotic with risk of metabolic changes, has documented baseline monitoring of weight or body mass index (BMI), blood pressure, fasting glucose or hemoglobin A1c, fasting	

Antipsychotics
Phone: 215-991-4300
Fax back to: 866-240-3712

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

Member Name:	Prescriber Name:		
<p>lipid panel, and extrapyramidal symptoms (EPS) using the Abnormal Involuntary Movement Scale (AIMS).</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>			
<p>Q11. If under 14 years of age, is prescribed the drug by or in consultation with one of the following: Pediatric neurologist, Child and adolescent psychiatrist, Child development pediatrician.</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> NA</p>			
<p>Q12. If 14 years of age or older, is prescribed the drug by or in consultation with one of the following: Pediatric neurologist, Child and adolescent psychiatrist, Child development pediatrician, General psychiatrist.</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>			
<p>Q13. The member has documented improvement in target symptoms.</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>			
<p>Q14. For an Antipsychotic with risk of metabolic changes, both of the following:</p> <table> <tr> <td><input type="checkbox"/> Documented monitoring of weight or BMI quarterly</td> <td><input type="checkbox"/> Documented monitoring of blood pressure, fasting glucose or hemoglobin A1c, fasting lipid panel, and EPS using AIMS after the first three months of therapy and then annually.</td> </tr> </table>		<input type="checkbox"/> Documented monitoring of weight or BMI quarterly	<input type="checkbox"/> Documented monitoring of blood pressure, fasting glucose or hemoglobin A1c, fasting lipid panel, and EPS using AIMS after the first three months of therapy and then annually.
<input type="checkbox"/> Documented monitoring of weight or BMI quarterly	<input type="checkbox"/> Documented monitoring of blood pressure, fasting glucose or hemoglobin A1c, fasting lipid panel, and EPS using AIMS after the first three months of therapy and then annually.		
<p>Q15. A documented plan is attached for taper/discontinuation of the Antipsychotic or there is rationale for continued use.</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>			
<p>Q16. For a non-preferred Antipsychotic with a therapeutically equivalent brand or generic that is preferred on the PDL, has a history of therapeutic failure of or a contraindication or an intolerance to the preferred therapeutically equivalent brand or generic that would not be expected to occur with the requested drug.</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>			



HEALTH PARTNERS PLANS
PRIOR AUTHORIZATION REQUEST FORM

Antipsychotics

Phone: 215-991-4300

Fax back to: 866-240-3712

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

Member Name:

Prescriber Name:

Q17. Additional Information:

Prescriber Signature

Date

v2026